| Agusta Olafsdottir, MD | |
|
621 S New Ballas Rd Ste 3016b, Mercy Clinic Adult Hospitalist, Saint Louis, MO 63141-8267 | |
| (314) 251-6339 | |
| (314) 251-4564 |
| Full Name | Agusta Olafsdottir |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 27 Years |
| Location | 621 S New Ballas Rd Ste 3016b, Saint Louis, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699888222 | NPI | - | NPPES |
| 0731307 | Medicaid | IA | |
| 27800 | Other | IA | WELLMARK BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 36729 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advocate Christ Hospital & Medical Center | Oak lawn, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocate Health And Hospitals Corporation | 7810800935 | 2422 |
News Archive
Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but that this treatment was also associated with a high rate of immune-related adverse events.
BioFocus and Almac have initiated a collaboration which will provide BioFocus customers with compound screening and profiling services using Almac's FLEXYTETM fluorescence lifetime assays.
French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.
PlusNews examines the recently approved grants under the Global Fund to Fight AIDS, Tuberculosis and Malaria's Transitional Funding Mechanism (TFM), stating, "Last week, the Fund announced that 45 new grant applications, from countries such as Burundi, Malawi and Swaziland, have been approved under the TFM."
› Verified 3 days ago
| Entity Name | Advocate Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700824455 PECOS PAC ID: 7810800935 Enrollment ID: O20031106000064 |
News Archive
Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but that this treatment was also associated with a high rate of immune-related adverse events.
BioFocus and Almac have initiated a collaboration which will provide BioFocus customers with compound screening and profiling services using Almac's FLEXYTETM fluorescence lifetime assays.
French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.
PlusNews examines the recently approved grants under the Global Fund to Fight AIDS, Tuberculosis and Malaria's Transitional Funding Mechanism (TFM), stating, "Last week, the Fund announced that 45 new grant applications, from countries such as Burundi, Malawi and Swaziland, have been approved under the TFM."
› Verified 3 days ago
| Entity Name | Advocate Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1629441027 PECOS PAC ID: 7810800935 Enrollment ID: O20151211000056 |
News Archive
Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but that this treatment was also associated with a high rate of immune-related adverse events.
BioFocus and Almac have initiated a collaboration which will provide BioFocus customers with compound screening and profiling services using Almac's FLEXYTETM fluorescence lifetime assays.
French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.
PlusNews examines the recently approved grants under the Global Fund to Fight AIDS, Tuberculosis and Malaria's Transitional Funding Mechanism (TFM), stating, "Last week, the Fund announced that 45 new grant applications, from countries such as Burundi, Malawi and Swaziland, have been approved under the TFM."
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Agusta Olafsdottir, MD 621 S New Ballas Rd Ste 3016b, Mercy Clinic Adult Hospitalist, Saint Louis, MO 63141-8267 Ph: (314) 251-6339 | Agusta Olafsdottir, MD 621 S New Ballas Rd Ste 3016b, Mercy Clinic Adult Hospitalist, Saint Louis, MO 63141-8267 Ph: (314) 251-6339 |
News Archive
Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but that this treatment was also associated with a high rate of immune-related adverse events.
BioFocus and Almac have initiated a collaboration which will provide BioFocus customers with compound screening and profiling services using Almac's FLEXYTETM fluorescence lifetime assays.
French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.
PlusNews examines the recently approved grants under the Global Fund to Fight AIDS, Tuberculosis and Malaria's Transitional Funding Mechanism (TFM), stating, "Last week, the Fund announced that 45 new grant applications, from countries such as Burundi, Malawi and Swaziland, have been approved under the TFM."
› Verified 3 days ago
Dr. Isik Turker, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 4921 Parkview Pl, Div Im Cardiology, Ste 8b, Saint Louis, MO 63110 Phone: 314-362-1291 Fax: 314-362-4278 | |
Conor Mccartney, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 915 N Grand Blvd, Saint Louis, MO 63106 Phone: 314-652-4100 | |
Dr. Faris Adam Bakeer, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1 Barnes Jewish Hospital Plz, Div Im Hospitalist, Saint Louis, MO 63110 Phone: 314-362-1700 Fax: 314-362-9878 | |
Rehan Rais, M.D. M.B.,B.S. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 660 S Euclid Ave, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Nathan Farkas, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1 Barnes Jew Hosp Plz, Saint Louis, MO 63110 Phone: 314-362-1930 | |
Dr. Nicole Foley, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Soumojit Ghosh, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3660 Vista Ave, Saint Louis, MO 63110 Phone: 314-977-6100 Fax: 314-977-6164 |